Literature DB >> 24122957

p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.

Megan A Chang1, Micaela Morgado, Curtis R Warren, Cimona V Hinton, Mary C Farach-Carson, Nikki A Delk.   

Abstract

BACKGROUND: Bone marrow stromal cell (BMSC) paracrine factor(s) can induce apoptosis in bone metastatic prostate cancer (PCa) cell lines. However, the PCa cells that escape BMSC-induced apoptosis can upregulate cytoprotective autophagy.
METHODS: C4-2, C4-2B, MDA PCa 2a, MDA PCa 2b, VCaP, PC3, or DU145 PCa cell lines were grown in BMSC conditioned medium and analyzed for mRNA and/or protein accumulation of p62 (also known as sequestome-1/SQSTM1), Microtubule-associated protein 1 light chain 3B (LC3B), or lysosomal-associated membrane protein 1 (LAMP1) using quantitative polymerase chain reaction (QPCR), Western blot, or immunofluorescence. Small interfering RNA (siRNA) was used to determine if p62 is necessary PCa cell survival.
RESULTS: BMSC paracrine signaling upregulated p62 mRNA and protein in a subset of the PCa cell lines. The PCa cell lines that were insensitive to BMSC-induced apoptosis and autophagy induction had elevated basal p62 mRNA and protein. In the BMSC-insensitive PCa cell lines, siRNA knockdown of p62 was cytotoxic and immunostaining showed peri-nuclear clustering of autolysosomes. However, in the BMSC-sensitive PCa cell lines, p62 siRNA knockdown was not appreciably cytotoxic and did not affect autolysosome subcellular localization.
CONCLUSIONS: A pattern emerges wherein the BMSC-sensitive PCa cell lines are known to be osteoblastic and express the androgen receptor, while the BMSC-insensitive PCa cell lines are characteristically osteolytic and do not express the androgen receptor. Furthermore, BMSC-insensitive PCa may have evolved a dependency on p62 for cell survival that could be exploited to target and kill these apoptosis-resistant PCa cells in the bone.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  autophagy; bone marrow; bone paracrine factors; p62/SQSTM1; prostate cancer

Mesh:

Substances:

Year:  2013        PMID: 24122957      PMCID: PMC3877418          DOI: 10.1002/pros.22737

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  51 in total

1.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Authors:  L Bubendorf; A Schöpfer; U Wagner; G Sauter; H Moch; N Willi; T C Gasser; M J Mihatsch
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

Review 2.  Deconvoluting the context-dependent role for autophagy in cancer.

Authors:  Eileen White
Journal:  Nat Rev Cancer       Date:  2012-04-26       Impact factor: 60.716

3.  Keap1 degradation by autophagy for the maintenance of redox homeostasis.

Authors:  Keiko Taguchi; Nanako Fujikawa; Masaaki Komatsu; Tetsuro Ishii; Michiaki Unno; Takaaki Akaike; Hozumi Motohashi; Masayuki Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

4.  Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells.

Authors:  Nikki A Delk; Mary C Farach-Carson
Journal:  Autophagy       Date:  2012-04-01       Impact factor: 16.016

5.  Foot-and-mouth disease virus induces autophagosomes during cell entry via a class III phosphatidylinositol 3-kinase-independent pathway.

Authors:  Stephen Berryman; Elizabeth Brooks; Alison Burman; Philippa Hawes; Rebecca Roberts; Christopher Netherton; Paul Monaghan; Matthew Whelband; Eleanor Cottam; Zvulun Elazar; Terry Jackson; Thomas Wileman
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

6.  Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue.

Authors:  H Kitamura; T Torigoe; H Asanuma; S-I Hisasue; K Suzuki; T Tsukamoto; M Satoh; N Sato
Journal:  Histopathology       Date:  2006-01       Impact factor: 5.087

7.  Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma.

Authors:  Daisuke Inoue; Takashi Suzuki; Yoichiro Mitsuishi; Yasuhiro Miki; Satoshi Suzuki; Shunichi Sugawara; Mika Watanabe; Akira Sakurada; Chiaki Endo; Akira Uruno; Hironobu Sasano; Takayuki Nakagawa; Kennichi Satoh; Nobuyuki Tanaka; Hiroshi Kubo; Hozumi Motohashi; Masayuki Yamamoto
Journal:  Cancer Sci       Date:  2012-02-21       Impact factor: 6.716

8.  Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer.

Authors:  Junjeong Choi; Woohee Jung; Ja Seung Koo
Journal:  Histopathology       Date:  2012-11-08       Impact factor: 5.087

9.  Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5.

Authors:  Dong-Yun Ouyang; Li-Hui Xu; Xian-Hui He; Yan-Ting Zhang; Long-Hui Zeng; Ji-Ye Cai; Shuai Ren
Journal:  Autophagy       Date:  2012-10-17       Impact factor: 16.016

10.  Tissue specific induction of p62/Sqstm1 by farnesoid X receptor.

Authors:  Jessica A Williams; Ann M Thomas; Guodong Li; Bo Kong; Le Zhan; Yuka Inaba; Wen Xie; Wen-Xing Ding; Grace L Guo
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

View more
  14 in total

1.  Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.

Authors:  Lorena A Puto; John Brognard; Tony Hunter
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

2.  Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR- PCa cells.

Authors:  Shayna E Thomas-Jardin; Mohammed S Kanchwala; Joan Jacob; Sana Merchant; Rachel K Meade; Nagham M Gahnim; Afshan F Nawas; Chao Xing; Nikki A Delk
Journal:  Prostate       Date:  2018-03-11       Impact factor: 4.104

3.  IL-1 induces p62/SQSTM1 and autophagy in ERα+ /PR+ BCa cell lines concomitant with ERα and PR repression, conferring an ERα- /PR- BCa-like phenotype.

Authors:  Afshan Fathima Nawas; Ragini Mistry; Shrinath Narayanan; Shayna Elizabeth Thomas-Jardin; Janani Ramachandran; Jananisree Ravichandran; Ebin Neduvelil; Krisha Luangpanh; Nikki Ayanna Delk
Journal:  J Cell Biochem       Date:  2018-10-15       Impact factor: 4.429

4.  RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.

Authors:  Shayna E Thomas-Jardin; Haley Dahl; Mohammed S Kanchwala; Freedom Ha; Joan Jacob; Reshma Soundharrajan; Monica Bautista; Afshan F Nawas; Dexter Robichaux; Ragini Mistry; Vanessa Anunobi; Chao Xing; Nikki A Delk
Journal:  Prostate       Date:  2019-11-15       Impact factor: 4.104

5.  Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways.

Authors:  X Cai-McRae; H Zhong; V Karantza
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

6.  IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.

Authors:  M A Chang; V Patel; M Gwede; M Morgado; K Tomasevich; E L Fong; M C Farach-Carson; Nikki A Delk
Journal:  J Cell Biochem       Date:  2014-12       Impact factor: 4.429

7.  NF-κB Signaling Activation Induced by Chloroquine Requires Autophagosome, p62 Protein, and c-Jun N-terminal Kinase (JNK) Signaling and Promotes Tumor Cell Resistance.

Authors:  Seungwon Yang; Lei Qiang; Ashley Sample; Palak Shah; Yu-Ying He
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

Review 8.  Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.

Authors:  Vladimir L Gabai; Victor I Shifrin
Journal:  Int Rev Immunol       Date:  2014-10       Impact factor: 5.311

9.  RNA-Seq and ChIP-Seq reveal SQSTM1/p62 as a key mediator of JunB suppression of NF-κB-dependent inflammation.

Authors:  Xiaoling Zhang; Jane Y Jin; Joseph Wu; Xiaoxia Qin; Robert Streilein; Russell P Hall; Jennifer Y Zhang
Journal:  J Invest Dermatol       Date:  2014-12-16       Impact factor: 8.551

Review 10.  P62: An emerging oncotarget for osteolytic metastasis.

Authors:  Jing Zhang; Zuozhang Yang; Jian Dong
Journal:  J Bone Oncol       Date:  2016-02-03       Impact factor: 4.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.